# Panitumumab

Source: https://onco.cc/drugs/panitumumab/  
OnCo record `panitumumab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Panitumumab is a fully human EGFR antibody, the preferred first-line partner for chemotherapy in left-sided, RAS-normal bowel cancer after the PARADIGM trial.

## Summary

Fully human IgG2 anti-EGFR; fewer infusion reactions than cetuximab and no ADCC. PARADIGM (2022) established superiority over bevacizumab in left-sided RAS wild-type disease; PRIME established it with FOLFOX. Partner of sotorasib in KRAS G12C mCRC (CodeBreaK 300, approved 2025). Same RAS-testing requirement and skin toxicity as cetuximab.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-07
- Brand: Vectibix
- Modality: Monoclonal antibody (anti-EGFR)
- Mechanism: High-affinity EGFR blockade without effector function.
- Approvals: US 2006: EGFR-expressing mCRC after chemotherapy (later RAS wild-type); US 2014: First-line RAS wild-type mCRC with FOLFOX; US 2025: KRAS G12C mCRC with sotorasib; EU 2007: Metastatic colorectal cancer; RAS wild-type from 2013; England (NICE) 2017: Previously untreated RAS wild-type metastatic colorectal cancer with FOLFOX or FOLFIRI
- Dosing: Intravenous; 6 mg/kg every 2 weeks

## Notes

- Colorectal cancer biomarkers: the PRIME extended RAS analysis moved the label from KRAS exon 2 to all RAS. Among 639 KRAS exon 2 wild-type patients, 108 (17%) had another RAS mutation and did worse on panitumumab-FOLFOX4, while the 512 with no RAS mutation gained 5.8 months of overall survival (26.0 against 20.2, hazard ratio 0.78) (Douillard 2013). Left-sided primary is the second requirement (Arnold 2017).

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Panitumumab
- FDA label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf
- NICE TA439: https://www.nice.org.uk/guidance/ta439
- EMA Vectibix: https://www.ema.europa.eu/en/medicines/human/EPAR/vectibix

## Connected records

- biomarkers: [KRAS G12C](https://onco.cc/biomarkers/kras-g12c/), [KRAS G12D (and other non-G12C KRAS mutations)](https://onco.cc/biomarkers/kras-g12d/), [RAS wild-type (extended KRAS and NRAS testing)](https://onco.cc/biomarkers/ras-wild-type/)
- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [KRAS G12C-mutant colorectal cancer](https://onco.cc/cancers/kras-g12c-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- targets: [EGFR](https://onco.cc/targets/egfr/)
- companies: [Amgen](https://onco.cc/companies/amgen/)
- pathways: [Colorectal cancer (KEGG map)](https://onco.cc/pathways/colorectal-cancer-signalling/), [RAS / RAF / MEK / ERK (MAPK)](https://onco.cc/pathways/ras-mapk/), [Receptor tyrosine kinase activation](https://onco.cc/pathways/rtk-activation/)
- trials: [A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer](https://onco.cc/trials/nct07659795/), [A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation](https://onco.cc/trials/nct07172919/), [A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil,](https://onco.cc/trials/nct06820463/), [CAIRO5](https://onco.cc/trials/cairo5/), [CHRONOS](https://onco.cc/trials/chronos/), [CodeBreaK 300](https://onco.cc/trials/codebreak-300/), [FOxTROT](https://onco.cc/trials/foxtrot/), [Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer](https://onco.cc/trials/nct06509126/), [Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery](https://onco.cc/trials/nct03384238/), [PARADIGM](https://onco.cc/trials/paradigm/), [Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies](https://onco.cc/trials/nct05786924/), [Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)](https://onco.cc/trials/nct05845450/), [PRIME](https://onco.cc/trials/prime/), [Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer](https://onco.cc/trials/nct06245356/), [Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal](https://onco.cc/trials/nct06252649/), [Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumu](https://onco.cc/trials/nct03635021/), [Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations](https://onco.cc/trials/nct06998940/), [Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal C](https://onco.cc/trials/nct02885753/), [Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial](https://onco.cc/trials/nct05863195/), [The Sagittarius Trial](https://onco.cc/trials/nct06490536/), [ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer](https://onco.cc/trials/nct06714357/)
- key papers: [CodeBreaK 300: sotorasib plus panitumumab in chemotherapy-refractory KRAS G12C colorectal cancer](https://onco.cc/key-papers/paper-codebreak-300-nejm-2023/), [Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer](https://onco.cc/key-papers/paper-misale-kras-acquired-resistance-anti-egfr-colorectal-nature-2012/), [Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer (PRIME)](https://onco.cc/key-papers/paper-douillard-prime-panitumumab-ras-nejm-2013/), [Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial (FOxTROT)](https://onco.cc/key-papers/paper-foxtrot-preoperative-chemotherapy-colon-jco-2023/), [Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials](https://onco.cc/key-papers/paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017/), [The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers](https://onco.cc/key-papers/paper-diaz-molecular-evolution-egfr-resistance-colorectal-nature-2012/)
- pairings: [Anti-EGFR antibody + chemotherapy in left-sided RAS/BRAF wild-type mCRC](https://onco.cc/pairings/anti-egfr-left-sided/)
- roadmaps: [Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation](https://onco.cc/roadmaps/colorectal-roadmap/)
- terms: [Anti-EGFR rechallenge](https://onco.cc/terms/anti-egfr-rechallenge/), [Colorectal cancer drugs in England: what NICE has recommended](https://onco.cc/terms/colorectal-uk-drug-access/), [Living with FOLFOX, CAPOX, FOLFIRI and the EGFR antibodies](https://onco.cc/terms/chemotherapy-side-effects-colorectal/)
- people: [Takayuki Yoshino](https://onco.cc/people/yoshino-takayuki/)
- drugs: [Tempus xT CDx](https://onco.cc/drugs/tempus-xt-cdx/), [therascreen companion diagnostic kits (KRAS, EGFR, PIK3CA, FGFR, BRAF)](https://onco.cc/drugs/therascreen-cdx/)

---
JSON: https://onco.cc/api/v1/entities/panitumumab.json